Short answer
Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 furnished under Item 2.02, with earnings details contained in the referenced exhibit.
Theravance Biopharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 furnished under Item 2.02, with earnings details contained in the referenced exhibit
- Disclosure not deemed filed under Exchange Act Section 18
- Exhibit 99.1 excluded from automatic incorporation into other SEC filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $20.7M, up 11% YoY, entirely from Viatris collaboration; YUPELRI implied share $24.7M
- YUPELRI U.S. net sales $70.7M, up 7% YoY; customer demand increased 10% and hospital doses 25%
- Zymeworks acquisition offers $17.00 cash per share plus CVR for 80% of future ampreloxetine monetization proceeds
- Closing expected in 2H 2026, subject to shareholder approval and customary conditions; transaction outcome remains the key catalyst
- Cash $387.7M with no debt; restructuring targets approximately $70M run-rate savings and $60M-$70M annualized cash flow beginning 2H 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Theravance Biopharma, Inc. 8-K filings
Get the next TBPH 8-K as it lands
Follow TBPH for push alerts, or ask the research agent what this filing means.